Skip to main content

Table 1 Patient characteristics

From: Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel

  N (%)
Patients enrolled and fully evaluable 74 (100)
Age, median value (range, IQR) 72 (49–82, 67–77)
ECOG Performance Status
 0–1 55 (74.3)
 2 19 (25.7)
Gleason score
 < 8 14 (22.2)
 ≥8 49 (77.8)
 Unknown/missing 11
Bone mts 72 (97.3)
Visceral mts 11 (15.1)
Liver mts 6 (8.2)
Lymph node mts 42 (57.5)
Presence of pain 25 (36.8)
Previous surgery (radical prostatectomy) 33 (44.6)
Previous radiotherapy (radical radiotherapy) 32 (43.2)
Number of previous treatments
 1 17 (23)
 2 43 (58.1)
 3 14 (18.9)
AR CN
 Normal 40 (54.0)
 Gain 34 (46.0)
Alkaline Phosphatase U/l, median value (range, IQR) 174 (54–965, 101–270)
Lactate Dehydrogenase U/l, median value (range, IQR) 240 (76–1177, 181–345)
Hemoglobin g/l, median value (range, IQR) 12.0 (9.0–15.0, 10.9–13.1)
Neutrophils count, median value (range, IQR) 4150 (840–8730, 3100–5360)
Lymphocytes count, median value (range, IQR) 1495 (90–26,000, 1120–1900)
Platelets count, median value (range, IQR) 236,000 (115,000–719,000, 196,000–295,000)
Serum Albumin g/l, median value (range, IQR) 31.3 (3.7–42.0, 4.0–40.0)
PSA, median value (range, IQR) 54.56 (2.69–5000, 19–175.60)
  1. Abbreviations: IQR interquartile range, ECOG PS Eastern Cooperative Oncology Group performance status, mts metastases, AR androgen receptor CN copy number PSA prostate-specific antigen